Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid in Breast Cancer Bone Metastases
NCT00321464Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2006
- Primary completion
- Jul 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in bone metastasis, sponsored by Amgen. Started Apr 2006; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT00321464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321464.